Phenotypic testing predicts virological response in successive protease inhibitor-based regimens

AIDS

Volumn 14, Issue 9, 2000, Pages

  Pérez Elías, Ma Jesús ^a   Lanier, Randall ^b   Muñoz, Vicente ^a   Garcia Arata, Isabel ^a   Casado, Jose L ^a   Marti Belda, Paloma ^a   Moreno, Ana ^a   Dronda, Fernando ^a   Antela, Antonio ^a   Marco, Santiago ^c   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (Spain)

Author keywords

Antiretroviral therapy; Cross resistance; Phenotype; Protease inhibitors; Recombinant viral assay; Resistance; Salvage therapy

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIVARIATE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; RISK; SALVAGE THERAPY; VIRUS LOAD;

ANTI-HIV AGENTS; COHORT STUDIES; CONFIDENCE INTERVALS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RNA, VIRAL; SALVAGE THERAPY; TIME FACTORS; VIRAL LOAD;

EID: 0033930825     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00002     Document Type: Article

References (24)

1. 1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality on patients with advance human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998, 338:853-860.
2. 2. Casado JL, Perez-Elias MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in HIV-infected patients. AIDS 1998, 12:F131-F135.
3. 3. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 1998, 279:1984-1991.
4. 4. Stephenson J. HIV drug resistance testing shows promise. JAMA 1999, 281:309-310.
5. 5. Hertogs K, de Bethune M, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
6. 6. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppresion of plasma viral RNA levels in subjets treated with ritonavir (Norvir) monotherapy. J Virol 1998, 72:5154-5164.
7. 7. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999, 13:F17-F21.
8. 8. Condra JH, Holder DJ, Schleif WA, et al. Genetics correlates of virological response to an indinavir-containing salvage regimen in patients with nelfinavir failure. Antiviral Ther. 1999, 4 (suppl 1):44.
9. 9. Deeks SG, Hellmann NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 1999, 179:1375-1381.
10. 10. Lanier ER, Stone C, Griffin P, et al. Phenotypic sensitivity to 1592 (abacavir) in the presence of multiple genotypic mutations: correlation with viral response. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998 [abstract 686].
11. 11. Durant J, Clevenvergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1993, 353:2195-2199.
12. 12. Baxter JD, Mayers DL, Wentworth DN, and the CPCRA 046 Study Team. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther 1999, 4 (suppl 1):43.
13. 13. Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventinal triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 1999, 13:F71-F77.
14. 14. Harrigan PR, Hertogs K, Verbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999, 13:1863-1871.
15. 15. Pauwels R, Hertogs K, Kemp S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, July 1999 [abstract 51].
16. 16. Saag M, Call S, Westfall A, et al. Predictive value of HIV phenotypic susceptibility testing in a clinical cohort. 39th Interscience Conference Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract LB-17].
17. 17. Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study. AIDS 1998, 12:619-624.
18. 18. Hertogs K, Mellors J, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998 [abstract 395].
19. 19. Dulioust A, Paulous S, Guillemot L, Delavalle AM, Bouê F, Clavel F. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol 1999, 73:850-854.
20. 20. Bossi PH, Legrand O, Faussat AM, et al. Expression and function of P-glycoproteine in HIV-infected patients receiving protease inhibitor. International Workshop on HIV Drug Resistance and Treatment Strategies. Antiviral Ther 1999, 4 (suppl 1):21.
21. 21. Robinson LH, Myers RE, Snowden et al. The influence of HIV-1 p7/p1 and p1/p6 cleavage site mutations on the assessment of phenotypic susceptibility to protease inhibitors in the recombinant virus assay. Antiviral Ther 1999 4 (suppl 1):32
22. 22. Hammer S, Demeter L, DeGruttola V, and the ACTG 372 Study Team. Relationship of Phenotypic and genotypic resistance profiles to virological outcome in a trial of abacavir, nelfinavir,-efavirenz and adefovir dipivoxil in patients with virological failure receiving indinavir. Antiviral Ther 1999, 4 (suppl 1):45.
23. 23. Garraffo R, Durant J, Clevenvergh P, et al. Independent benefit of sufficient drug levels and genotype analysis in salvage therapy: pharmacological data of the VIRADAPT Study. 39th Interscience Conference Antimicrobial Agents and Chemotherapy. San Francisco, September 1999 [abstract 1166].
24. 24. Casado JL, Sabido R, Perez-Elias MJ, et al. Percentage of adherence correlates with the risk of protease inhibitor (PI) treatment failure in HIV-infected patients. Antiviral Ther 1999, 4:157-161.